Application 208711
- Type
- NDA
- Sponsor
- NOVARTIS
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | EGATEN | TRICLABENDAZOLE | TABLET;ORAL | 250MG | Yes | Yes |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0078-0937 | EGATEN | triclabendazole | Novartis Pharmaceuticals Corporation | NDA | Current |
| 0078-0937 | EGATEN | triclabendazole | Novartis Pharmaceuticals Corporation | NDA | Current |
| 0078-0937 | EGATEN | triclabendazole | Novartis Pharmaceuticals Corporation | NDA | Current |
| 0078-0937 | EGATEN | triclabendazole | Novartis Pharmaceuticals Corporation | NDA | Current |
| 0078-0937 | EGATEN | triclabendazole | Novartis Pharmaceuticals Corporation | NDA | Current |
| 0078-0937 | EGATEN | triclabendazole | Novartis Pharmaceuticals Corporation | NDA | Current |